Evolus has secured exclusive U.S. distribution rights to Profhilo, an IBSA hyaluronic acid injectable biostimulator, under a 15-year licensing agreement with no upfront payment. The deal signals Evolus's strategy to broaden its injectables footprint beyond Jeuveau (neuromodulator) and into the growing biostimulator category, where practices increasingly stack HA-based products alongside toxin and filler for volumization and collagen remodeling.